Arcturus' COVID-19 mRNA Vaccine Candidate To Target Variants, Trial To Start In Vietnam

  • The Vietnam Ministry of Health has signed off Arcturus Therapeutics Holdings Inc's ARCT Clinical Trial Application (CTA) to advance ARCT-154 COVID19 vaccine candidate targeting variants of concern.
  • The ARCT-154 Phase 1/2/3 clinical study is a randomized, observer-blind, placebo-controlled design and is sponsored and entirely funded by Arcturus' manufacturing partner Vinbiocare, a subsidiary of Vingroup. 
  • The study will assess the safety, immunogenicity, and efficacy of the SARS-CoV-2 self-amplifying mRNA vaccine in adults 18 years or older and enroll up to 21,000 participants across the 3 phases, with 20,000 in Phase 3. 
  • Primary endpoints include safety and efficacy with immunogenicity being evaluated in a subgroup.
  • If the study proves successful at interim evaluations, Emergency Use Approval (EUA) by the Vietnam Ministry of Health is anticipated in December 2021.
  • Vinbiocare and Arcturus also announced to establish a manufacturing plant for the COVID-19 vaccines.
  • Price Action: ARCT shares are up 9.10% at $34.16 during the market session on the last check Monday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!